Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …

In the last century, life expectancy has increased considerably, thanks to the introduction of
antibiotics, hygiene and vaccines that have contributed to the cure and prevention of many …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

Current World Health Organization guidelines for the formulation of treatment regimens for
multidrug-resistant tuberculosis (MDR-TB) pay too little attention to the microbiological …

Resistance to isoniazid (INH) is common and increases the possibility of acquiring multidrug-
resistant tuberculosis. For this study, isoniazid-loaded nanostructured lipid carriers (INH …

Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB,
respectively) continue to represent a challenge for clinicians and public health authorities …

Tuberculosis (TB) is a contagious airborne disease caused by Mycobacterium tuberculosis,
which primarily affects human lungs. The progression of drug-susceptible TB to drug …

Tuberculosis (TB) remains a threat to public health and is the leading cause of death
globally. Isoniazid (INH) is an important first-line agent for the treatment of TB considering its …

Abstract Purpose of Review Tuberculous meningitis is the most devastating manifestation of
infection with Mycobacterium tuberculosis and represents a medical emergency …

Isoniazid (INH) is one of the key molecules employed in the treatment of tuberculosis (TB),
the most deadly infectious disease worldwide. However, the efficacy of this cornerstone drug …